Zhejiang Huahai Pharmaceutical operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Zhejiang Huahai Pharmaceutical with three other
companies in this sector in China:
Tianjin Chase Sun Pharmaceutical Company Limited
sales of 3.87 billion Chinese Renmimbi [US$582.83 million]
of which 49%
Shijiazhuang Yiling Pharmaceutical Co Ltd
(3.82 billion Chinese Renmimbi [US$575.75 million]
of which 100%
was Medicine), and
Shenzhen Salubris Pharmaceuticals Co Ltd
(3.83 billion Chinese Renmimbi [US$577.78 million]
of which 100%
was Pharmaceutical Manufacturing).
Zhejiang Huahai Pharmaceutical reported sales of 4.09 billion Chinese Renmimbi (US$616.87 million)
December of 2016.
increase of 16.9%
versus 2015, when the company's sales were 3.50 billion Chinese Renmimbi.
Sales at Zhejiang Huahai Pharmaceutical have increased during each of the previous five years
(and since 2011, sales have increased a total of 124%).
Sales of Technical Service saw an increase
that was more than double the company's growth rate: sales were up
250.0% in 2016, from
4.39 million Chinese Renmimbi to 15.37 million Chinese Renmimbi.
Zhejiang Huahai Pharmaceutical also saw significant increases in sales in
Drug Sale (up 22.3% to 1.96 billion Chinese Renmimbi)
Not all segments of Zhejiang Huahai Pharmaceutical experienced an increase in sales in 2016:
sales of Other fell 100.0% to 12,478.64 Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).